8/1012 sources · 5 publishersUpdated Oct 30, 11:54 UTC
Insmed raises 2026 revenue guidance after strong third-quarter results
Insmed reported third-quarter 2026 revenue of $524.4M, up 268% year over year, with a net loss of $100.3M. BRINSUPRI generated $400.1M and ARIKAYCE generated $124.4M during the quarter. Insmed raised full-year 2026 revenue guidance for BRINSUPRI to $1.35B-$1.4B and for ARIKAYCE to $460M-$470M.
Why it matters
The higher guidance raises the company’s expected 2026 product revenue outlook, while the reported net loss shows Insmed remains unprofitable. Insmed expects to reach cash-flow positivity in 2027, according to the company’s earnings-call update.
Key facts
- 1Third-quarter 2026 revenue was $524.4M, up 268% year over year, and net loss was $100.3M. tradingview.com
- 2BRINSUPRI generated $400.1M in third-quarter revenue and ARIKAYCE generated $124.4M. tradingview.com
- 3Insmed raised 2026 BRINSUPRI revenue guidance to $1.35B-$1.4B and ARIKAYCE guidance to $460M-$470M. rttnews.com
- 4The company received FDA priority review for ARIKAYCE’s supplemental application, with a target action date of Jan. 28, 2027. finance.yahoo.com
Open questions
- Material 5 reports quarterly revenue of $425.5M, compared with $524.4M reported by the other earnings materials for the same quarter.
- Material 5 reports prior or alternative 2026 guidance of $1.25B-$1.4B for BRINSUPRI and $450M-$470M for ARIKAYCE, differing from the raised ranges reported elsewhere.
Summary written by AlphAI AI Desk from 12 of 12 sources. Not investment advice. Figures are as stated by the linked sources.